Related references
Note: Only part of the references are listed.AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells
Zhirui Zhang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo
Zhongwei Liu et al.
ARCHIVES OF TOXICOLOGY (2019)
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Xuejiao Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma
Tabea C. Froehlich et al.
BLOOD (2019)
BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
Yihong Zhan et al.
CELL AND BIOSCIENCE (2019)
Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
Vasanti Suvarna et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
Wanhong Xu et al.
NEOPLASIA (2019)
Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning
Eliseos J. Mucaki et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance
Harun Patel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Venetoclax for the treatment of patients with chronic lymphocytic leukemia
Jennifer Crombie et al.
FUTURE ONCOLOGY (2017)
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
Zhongwei Liu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells
Zheng-Hai Tang et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro
Qing-huan Lin et al.
ACTA PHARMACOLOGICA SINICA (2017)
Caspase involvement in autophagy
Panagiotis Tsapras et al.
CELL DEATH AND DIFFERENTIATION (2017)
Survivin: a unique target for tumor therapy
Himani Garg et al.
CANCER CELL INTERNATIONAL (2016)
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
Laurel T. Bate-Eya et al.
ONCOTARGET (2016)
The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update
Waseem Ahmad Siddiqui et al.
ARCHIVES OF TOXICOLOGY (2015)
Survivin: A molecular biomarker in cancer
Praveen Kumar Jaiswal et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2015)
p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells
Jing Su et al.
ONCOLOGY REPORTS (2015)
Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review
Jie Zhang et al.
ONCOTARGETS AND THERAPY (2015)
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Elena Galvani et al.
ONCOTARGET (2015)
Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer
Tangfeng Lv et al.
ONCOTARGET (2015)
Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells
Chihuei Wang et al.
PLOS ONE (2015)
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21(CIP1/WAF1) in human cancer cells
Jingru Li et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Caspases: A Molecular Switch Node in the Crosstalk between Autophagy and Apoptosis
Haijian Wu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation
Man Zou et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
Jun Chen et al.
MOLECULAR CANCER THERAPEUTICS (2011)
p53 binding to the p21 promoter is dependent on the nature of DNA damage
Ewelina Bodzak et al.
CELL CYCLE (2010)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Share Paper
